Role of centchroman versus danazol in treatment of benign breast disorders

Hanuman Ram Khoja, Bodu Ram Barala, Saurabh Sharma, Prabha Om, Devendra Saini
In: International Surgery Journal · 2021 · vol. 8(2) , pp. 616 · doi:10.18203/2349-2902.isj20210372 · W3126700122
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Centchroman demonstrated superior efficacy, symptom relief, and lower cost compared to danazol for treating benign breast disorders, though menstrual irregularities were more frequent.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This prospective study compared centchroman versus danazol for symptom relief, reduction in nodularity and lump size, recurrence, cost, and side effects in 250 patients with benign breast disorders treated between May 2018 and September 2019 in surgical OPD settings in Jaipur. The authors reported greater tolerance and improvements in symptoms with centchroman than danazol (100% vs 92.8%), along with less recurrence in the centchroman group. Side effects differed between groups, with menstrual irregularities more common in the centchroman group. The paper does not state detailed limitations in the provided text, but it frames conclusions around long-term safety, effectiveness, and lower cost; it does not explicitly discuss endometriosis or adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: The breast is a dynamic structure that undergoes cyclical changes throughout the menstrual cycle. Any aberration from normal physiological changes in breast produces different problem in breast. Many drugs are used for treatment for these disorders like Danazol, Bromocriptine, Tamoxifen and LH-RH analogue but still no consensus for any drug is present.Methods: The aim of our study was to analyze the effectiveness of drug Centchroman and its comparison with Danazol in treatment of benign breast disorders in respect to symptoms relief, decrease in nodularity and lump size, recurrence, cost and side effects of drug. This prospective study was conducted on 250 patients of benign breast disorders attending surgical OPD between May 2018 to September 2019 in SMS medical college and Hospital, Jaipur.Results: Tolerance and improvements in symptoms in centchroman group was more than danazol (100% vs 92.8%) with less recurrence in former group. While side effects varied between the two groups with menstrual irregularities more common in centchroman group.Conclusions: The study shows that centchroman is safe, more effective and less expensive to Danazol for the treatment of benign breast disorders in long term.
Full text 2,371 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Background

The breast is a dynamic structure that undergoes cyclical changes throughout the menstrual cycle. Any aberration from normal physiological changes in breast produces different problem in breast. Many drugs are used for treatment for these disorders like Danazol, Bromocriptine, Tamoxifen and LH-RH analogue but still no consensus for any drug is present.

Methods

The aim of our study was to analyze the effectiveness of drug Centchroman and its comparison with Danazol in treatment of benign breast disorders in respect to symptoms relief, decrease in nodularity and lump size, recurrence, cost and side effects of drug. This prospective study was conducted on 250 patients of benign breast disorders attending surgical OPD between May 2018 to September 2019 in SMS medical college and Hospital, Jaipur.

Results

Tolerance and improvements in symptoms in centchroman group was more than danazol (100% vs 92.8%) with less recurrence in former group. While side effects varied between the two groups with menstrual irregularities more common in centchroman group.

Conclusions

The study shows that centchroman is safe, more effective and less expensive to Danazol for the treatment of benign breast disorders in long term. Metrics

References

Tejwani PL, Srivastava A, Nerkar H, Dhar A, Hari S, Thulkar S, et al. Centchroman regresses mastalgia: a randomized comparison with danazol. Indian J Surg. 2011;73(3):199-205. Dhar A, Srivastava A. Role of centchroman in regression of mastalgia and fibroadenoma. World J Surg. 2007;31(6):1178-84. Khanna S. Comparative evaluation of the role of Centchroman in benign breast diseases: Int J Biol Med Res. 2016;7(2):5563-8. Greenblatt RB, Dmowski WP, Mahesh VB, Scholer HFL. Clinical studies with an antigonadotropin-danazol. Fertil Steril. 22:102,1971 Pye J, Mansel R, Hughes L. Clinical experience of drug treatments for mastalgia. The Lancet. 1985;326(8451):373-7. Gateley C, Mansel, R. Management of the painful and nodular breast. British Medical Bulletin. 1991;47(2):284-94. Ortiz-Mendoza CM, Olvera-Mancilla M. Danazol effectively in control of moderate to severe mastalgia. Cir. 2004;72(6):479-82.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (7)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T10:35:03.967074+00:00
License: CC0 · commercial use OK